Splash Beverage Invests CDN$300K in Avicanna, Securing 2M Shares and Warrants
SBEV•On June 9, Splash Beverage completed a CDN$300,000 investment in Avicanna, acquiring 2,000,000 shares and 1,000,000 warrants to accelerate its pivot into cannabinoid healthcare. Avicanna offers a commercial-stage portfolio including Turnerox™ epilepsy treatment, MyMedi.ca patient-care services, and pharmaceutical-grade cannabinoid manufacturing in Canada and Colombia.
1. Investment Details
On June 9, Splash Beverage deployed CDN$300,000 into Avicanna’s non-brokered private placement, acquiring 2,000,000 common shares and 1,000,000 warrants. This marks Splash’s initial capital allocation toward transforming from a beverage company into a cannabinoid-focused healthcare platform.
2. Avicanna’s Biopharmaceutical Capabilities
Avicanna operates a commercial-stage portfolio that includes Turnerox™, an approved cannabidiol therapy for severe epilepsy, alongside clinical programs targeting pain, inflammation, and dermatological conditions. Its MyMedi.ca platform delivers pharmacist-led patient care, insurance adjudication, and physician-guided access, backed by pharmaceutical-grade manufacturing in Canada and Colombia.
3. Strategic Rationale and Growth Outlook
Splash’s management cites Avicanna’s intellectual property, clinical development expertise, healthcare-system integration, and debt-free balance sheet as key differentiators. The investment positions Splash to leverage established reimbursement infrastructure and regulated frameworks as U.S. medical cannabinoid regulations evolve.
